Page last updated: 2024-11-02

pioglitazone and Congestive Ophthalmopathy

pioglitazone has been researched along with Congestive Ophthalmopathy in 4 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes."7.77Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011)
"Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes."3.77Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, AM1
Yin, HY1
Chen, A1
Liu, YW1
Chuang, MC1
He, H1
Tighe, S1
Sheha, H1
Liao, SL1
Antonelli, A3
Ferrari, SM3
Fallahi, P3
Frascerra, S2
Santini, E1
Franceschini, SS2
Ferrannini, E3
Piaggi, S1
Paolicchi, A1
Salvi, M1
Ruffilli, I1
Pupilli, C1
Bernini, G1
Sellari-Franceschini, S1
Gelmini, S1

Other Studies

4 other studies available for pioglitazone and Congestive Ophthalmopathy

ArticleYear
Celecoxib and Pioglitazone as Potential Therapeutics for Regulating TGF-β-Induced Hyaluronan in Dysthyroid Myopathy.
    Investigative ophthalmology & visual science, 2016, Apr-01, Volume: 57, Issue:4

    Topics: Adult; Blotting, Western; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibit

2016
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:5

    Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; En

2009
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:2

    Topics: Adipocytes; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chemokine CXCL10; Femal

2011
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
    The Journal of endocrinology, 2012, Volume: 213, Issue:2

    Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy;

2012